Universe Pharmaceuticals Inc

Universe Pharmaceuticals led Monday's biotech gainers with shares soaring nearly 100% after its SEC filing showed a narrowed net loss for the six months ended March 31, 2026. Revenue was $9.03 million and net loss was $1.55 million, or $2.76 per share, compared with a net loss of $3.28 million, or $9.44 per share, in the year-ago period. Cumberland Pharmaceuticals jumped over 38% ahead of its second-quarter 2026 results due Tuesday, following last month's sale of its branded portfolio to an Apotex Health unit for $100 million in cash. Autolus Therapeutics gained over 22% after reporting preliminary second-quarter AUCATZYL net product revenue of approximately $45 million, up 70% sequentially and more than 100% year over year. Other notable movers included Pulmonx, up over 30% after reaffirming full-year 2026 revenue guidance of $90 million to $92 million, and CAMP4 Therapeutics, which rose over 22% after receiving Australian clearance to begin a Phase 1/2 trial of CMP-002, satisfying a condition to raise up to $50 million in a private placement.

Universe Pharmaceuticals led biotech gainers Monday, soaring more than 300% after announcing a strategic acquisition to expand its pharmaceutical patent portfolio. The company agreed to acquire 100% of Best Praise International Limited, which holds five Chinese patents covering elderly healthcare, cognitive health, cardiovascular applications, antibacterial compounds, and drug delivery technologies, for US$10.75 million payable in 4,376,552 Class A ordinary shares. The deal is expected to close in the third quarter of 2026, and UPC closed at $12.18, up 311.49%. Other notable movers included Decoy Therapeutics, which jumped over 70% on a private placement financing of up to $21 million, and QuidelOrtho, up over 30% on reports it is exploring the sale of its point-of-care testing business for approximately $1.5 billion. SELLAS Life Sciences gained more than 24% as its Phase 3 REGAL trial of GPS in acute myeloid leukemia nears its final analysis, with 78 of the required 80 events reported as of May 11, 2026.

Universe Pharmaceuticals has agreed to acquire Best Praise International Limited for approximately US$10.75 million, gaining five pharmaceutical patents in China. The purchase will be paid entirely with 4,376,552 Class A ordinary shares of Universe Pharmaceuticals. The patent portfolio covers age-related diseases, neurodegenerative conditions, cognitive disorders, cardiovascular applications, antibacterial compounds, and drug delivery technologies. CEO Gang Lai said the acquisition broadens the company's pipeline and supports long-term growth, complementing its focus on elderly healthcare. The deal, approved by Universe's board, is expected to close in the third quarter of 2026.